令人痛苦的整合素拮抗剂？
Agonizing integrin antagonists?
作者信息
Weis Sara M, Stupack Dwayne G, Cheresh David A
机构信息
Moores UCSD Cancer Center and Department of Pathology, University of California, San Diego, La Jolla, CA 92093, USA.
出版信息
Cancer Cell. 2009 May 5;15(5):359-61. doi: 10.1016/j.ccr.2009.04.005.
PMID:19411065
Abstract
A recent study published in Nature Medicine reports that low-dose treatment with RGD-mimetic integrin inhibitors may paradoxically enhance angiogenesis and tumor growth. This work implies that delivery of these agents should be redesigned in order to avoid nanomolar plasma concentrations and to improve their efficacy to treat human cancers.
摘要
最近发表在《自然·医学》上的一项研究报告称，用模拟RGD的整合素抑制剂进行低剂量治疗可能会反常地促进血管生成和肿瘤生长。这项研究表明，应该重新设计这些药物的给药方式，以避免纳摩尔级别的血浆浓度，并提高其治疗人类癌症的疗效。
Zotero 插件